MetaCap

InfuSystems Holdings Inc. (INFU)

NYSE: INFUHealth CareMedical/Dental InstrumentsUSD

14.35+0.29 (+2.06%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

INFU stock chart

Technical analysis

Key statistics

All statistics
Market cap
$287.48M
52-week range
7.29 – 15.47
Day range
13.77 – 14.44
Volume / Avg
214.71K / 136.60K
Beta
—

52-week range

$7.29$15.47

INFU stock today

Shares of InfuSystems (INFU) finished higher on Nov 20 at $14.35, a gain of 2.06% or $0.29 per share, versus the S&P 500's 3.70% decline. At this level, INFU sits near the top of its 52-week range of $7.29 to $15.47: 7.2% below the high, set on Nov 11, 2026 and 96.8% above the low. INFU is up 60.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 51.7%.

InfuSystems trades at 32.6x its trailing twelve-month earnings per share of $0.44. Its forward P/E of 25.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About InfuSystems

Company profile

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions. The company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.

Industry
Medical/Dental Instruments
CEO
Ms. Carrie A. Lachance B.S.N., M.B.A., R.N.
Headquarters
Rochester Hills, MI
Employees
461

Financial highlights

Full financials

In fiscal 2025, InfuSystems generated $143.4 million in revenue, up 6.4% from fiscal 2024, its 7th consecutive year of revenue growth. Net income was $6.6 million (+182.6% year over year), for a net margin of 4.6% versus a median of 1.4% in the prior 5 years. Gross margin was 56.0% (up from 52.2%) and operating margin 8.3%.

InfuSystems annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$143.44M$134.86M$125.78M$109.91M$102.38M
Growth+6.36%+7.22%+14.44%+7.36%+5.13%
Net income$6.63M$2.35M$872.00K$18.00K$1.42M
EPS (diluted)$0.31$0.11$0.04$0.00$0.06

Analyst forecast

Forecast

Consensus (3 analysts)

strong_buy

Avg. price target

$18.50+28.92%

  • Strong buy 0
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $17.50High $20.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$0.15 vs —

INFU news

All INFU news

InfuSystems peers

Health Care sector
INFU peer companies
CompanyPrice% ChgMarket capCompare
TMCITreace Medical Concepts Inc.4.31-0.92%$282.56Mvs INFU
NPCENeuropace Inc.7.95-2.33%$273.89Mvs INFU
SSIISS Innovations International Inc.1.27-0.78%$254.86Mvs INFU
OFIXOrthofix Medical Inc.6.07-4.26%$247.41Mvs INFU
OSUROraSure Technologies Inc.3.46-4.16%$238.90Mvs INFU
PROFProfound Medical Corp.6.38-3.19%$233.68Mvs INFU
EMBCEmbecta Corp.6.02-2.75%$341.09Mvs INFU
BWAYBrainsWay Ltd. ADR8.48-2.86%$341.35Mvs INFU

Indexes, lists and sector

InfuSystems stock FAQ

What is InfuSystems's stock price today?

INFU last traded at $14.35 as of Nov 20, 4:00 PM EST, up 2.06% on the day. Prices are delayed at least 15 minutes.

What is INFU's P/E ratio?

INFU trades at a trailing P/E ratio of 32.61 and a forward P/E of 25.63.

Who is InfuSystems's CEO?

Ms. Carrie A. Lachance B.S.N., M.B.A., R.N. is the chief executive officer of InfuSystems Holdings Inc., which has about 461 employees.

What is the INFU 52-week high?

The 52-week high for INFU is $15.47 and the 52-week low is $7.29. The stock is currently 7.2% below its high.

Compare INFU